Quan Lucinda Y. 4
4 · Aligos Therapeutics, Inc. · Filed Oct 20, 2020
Insider Transaction Report
Form 4
Quan Lucinda Y.
See Remarks
Transactions
- Conversion
Series B-1 Preferred Stock
2020-10-20−1,697→ 0 total(indirect: See footnote)→ Common Stock (1,697 underlying) - Conversion
Common Stock
2020-10-20+726→ 9,258 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2020-10-20−6,835→ 0 total(indirect: See footnote)→ Common Stock (6,835 underlying) - Conversion
Series B-2 Preferred Stock
2020-10-20−726→ 0 total(indirect: See footnote)→ Common Stock (726 underlying) - Conversion
Common Stock
2020-10-20+1,697→ 8,532 total(indirect: See footnote) - Conversion
Common Stock
2020-10-20+6,835→ 6,835 total(indirect: See footnote)
Holdings
- 375,547
Common Stock
Footnotes (2)
- [F1]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
- [F2]Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010.